Trial · NCT06979791
Comparing Two Doses of Midazolam With Added Dexmedetomidine for Kids Before Surgery
NCT06979791, Phase 2, Completed, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Comparing Two Doses of Midazolam With Added Dexmedetomidine for Kids Before Surgery. Trials, record NCT06979791. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06979791
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparing Two Doses of Midazolam With Added Dexmedetomidine for Kids Before Surgery
- NCT number
- NCT06979791
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 60 participants, actual
- Lead sponsor
- Cairo University
- Conditions
- Preoperative Anxiety Experienced by the Pediatric Patient, Preoperative Anxiety
- Interventions
- Dexmedetomidine + Midazolam 0.4 mg/kg, Dexmedetomidine + Midazolam 0.2 mg/kg
- First posted
- 2025-05-20
- Last updated
- 2026-09-17
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mask Acceptance Score (MAS) at time of induction | At the time of induction (approximately 30 minutes after premedication) | Mask acceptance will be assessed at the time of anesthesia induction using the Mask Acceptance Score (MAS). A score of 1 or 2 will be considered satisfactory (excellent/good), while scores of 3 or 4 will be considered unsatisfactory. The percentage of children with satisfactory mask acceptance will be compared between groups. |
| Secondary | Sedation Level (MOASS) at 15 and 30 minutes after premedication | 15 minutes and 30 minutes after drug administration | Sedation will be evaluated using the Modified Observer's Assessment of Alertness/Sedation Scale (MOASS). Scores will be recorded at 15 and 30 minutes after intranasal drug administration. |
| Secondary | Child-Parent Separation Score | Approximately 30 minutes after premedication (at time of separation) | Measured using the Child-Parent Separation Scale at the time of separation from parents. Scores of 1 or 2 indicate satisfactory separation; score of 3 indicates poor separation. |
| Secondary | Heart Rate | Baseline, 30minutes after medication and at the time of anesthesia induction. | Heart rate will be monitored at baseline, 30minutes after medication and at the time of anesthesia induction. Mean heart rate values will be compared between the two groups. |
| Secondary | Blood Pressure | Baseline, 30minutes after medication and at the time of anesthesia induction. | Mean blood pressure will be monitored at baseline, 30minutes after medication and at the time of anesthesia induction. Mean blood pressure values will be compared between the two groups. |
| Secondary | Time to Recovery (Modified Aldrete Score ≥ 9) | From cessation of inhalational anaesthesia until Modified Aldrete Score ≥9 is achieved. | The time from cessation of inhalational anaesthesia to achieving a Modified Aldrete Score of ≥9 will be recorded. |
| Secondary | Time to Extubation | The time between the cessation of inhalational anesthesia and the removal of the endotracheal tube. | The time from the cessation of inhalational anesthesia and the removal of the endotracheal tube will be recorded. |
| Secondary | Perioperative Adverse Events | From the time of drug administration until discharge from the Post-Anesthesia Care Unit (PACU) to the Ward | Incidence of adverse effects such as nasal irritation, Post Operative nausea\& vomiting will be recorded and compared between groups. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06979791
GET https://conductscience.org/api/trials/v1/NCT06979791/registered